Bergamo

• TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of ly … Pending
  2025-521827-61-00 4 refractory/relapsed multiple myeloma
• A Study to Determine the Effectiveness of a Test Drug ([68Ga]BED003) for the Detection of Pancreatic, Colorectal, Gastric, Breast and Ovaria … Pending
  2025-521983-36-00 4 Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenoc
• A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma Pending
  2025-522523-96-00 1 T-cell Non-Hodgkin Lymphoma
• Administration of a new gene therapy to patients affected by Hereditary Spastic Paraplegia Type 50 (SPG50) Pending
  2025-522603-15-00 4 Hereditary Spastic Paraplegia Type 50 (SPG50)
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 5 Relapsed/refractory primary central nervous system lymphoma
• DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending
  2025-523895-22-00 4 Non-small cell lung cancer (NSCLC)
• Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Pending
  2025-523947-36-00 4 Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherap
• A Phase 2 Study of JNJ-79635322 in Participants with RRMM Recruiting
  2025-521976-80-00 4 2026-05-28 Relapsed or Refractory Multiple Myeloma (RRMM)
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipien … Recruiting
  2025-521074-34-00 4 2026-05-15 Allogeneic peripheral hematopoietic stem cell transplant
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults … Recruiting
  2024-519830-22-00 5 2026-04-27 Heart failure due to systemic left ventricular systolic dysfunction
• A Study of how the Medicine Called "Etrasimod" Works in Children With the gut Disease Called Ulcerative Colitis Recruiting
  2025-523100-77-00 4 2026-04-23 Ulcerative Colitis
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth … Recruiting
  2025-522492-28-00 4 2026-03-13 AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis,
• A study to learn more about the change in the blood levels of transthyretin when participants with transthyretin amyloidosis with cardiomyop … Recruiting
  2025-521831-35-00 6 2026-02-12 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia

Showing 25–48 of 373 trials